Q3 2024 Financial Results and Business Update | November 13, 2024
ANKET® | Antibody-based NK cell Engager Therapeutics
Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma
Harnessing the power of NK cells to develop therapeutic antibodies
Collaborating with a strong network to advance our pipeline